Parallax Volatility Advisers
CRVS icon

Parallax Volatility Advisers’s Corvus Pharmaceuticals CRVS Stock Holding History

Parallax Volatility Advisers’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,302
Closed -$13K – 2507
2017
Q4 		$13K Buy
+1,302
New +$16.7K ﹤0.01% 3763

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Parallax Volatility Advisers's CRVS Position: Q1 2018 in Review

Parallax Volatility Advisers sold out of Corvus Pharmaceuticals (CRVS) in Q1 2018, closing a stake of 1,302 shares — an estimated $13K sold.

Parallax Volatility Advisers first reported a position in CRVS in Q4 2017 and held it in 1 quarter. The position peaked at $13K in Q4 2017. 55 funds tracked by Wall St. Rank hold CRVS as of Q1 2018.

  • Parallax Volatility Advisers reported no remaining Corvus Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 1,302 Corvus Pharmaceuticals shares in Q1 2018, an estimated $13K.
  • Parallax Volatility Advisers first reported a position in Corvus Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Parallax Volatility Advisers's Corvus Pharmaceuticals position peaked at $13K in Q4 2017.
  • 55 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2018.

Based on Parallax Volatility Advisers's 13F filing for Q1 2018, filed 15 May 2018.